3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Carboplatin
25
Paclitaxel
24
pembrolizumab
22
Cyclophosphamide
14
Gemcitabine
10
Capecitabine
10
Doxorubicin
9
Specimen Handling
8
Nivolumab
8
Taxes
7
Magnetic Resonance Spectroscopy
7
sacituzumab govitecan
6
olaparib
6
Cisplatin
6
eribulin
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
capivasertib
4
Epirubicin
4
Docetaxel
4
Biopsy
4
niraparib
3
Vinorelbine
3
Radiation
3
Fulvestrant
3
Blood Specimen Collection
3
trastuzumab deruxtecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Triple Negative Breast Neoplasms
×
futibatinib
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled